isatin has been researched along with Disease Models, Animal in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 4 (26.67) | 29.6817 |
| 2010's | 8 (53.33) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Deng, X; Fang, T; Han, Z; Li, L; Li, T; Lv, H; Qian, C; Si, X; Wang, J; Wu, S; Xia, J; Zhang, W; Zhou, Y; Zhu, Z | 1 |
| Ávila, DS; Fidélis, EM; Gervini, VC; Gutierrez, MEZ; Martins, BB; Pinton, S; Puntel, RL; Roos, DH; Savall, ASP | 1 |
| Buneeva, OA; Kapitsa, IG; Kopylov, AT; Medvedev, AE; Nerobkova, LN; Zgoda, VG | 1 |
| Ahmed, MN; Arif, M; Atiq, A; Khan, A; Khan, S; Kim, YS; Naveed, M; Zeeshan, S | 1 |
| Brito, AR; de Almeida, AC; de Faria, FM; Dunder, RJ; Luiz-Ferreira, A; Manzo, LP; Socca, EA | 1 |
| Fernandes, PD; Figueiredo, GS; Pinto, AC; Silva, BV; Zardo, RS | 1 |
| Ansari, A; Bari, S; Nikalje, AP; Ugale, V | 1 |
| Barré, L; Delamare, J; Dhilly, M; Fraser, BH; Greguric, I; Krause-Heuer, AM; Matesic, L; Médoc, M; Sobrio, F; Toutain, J; Touzani, O | 1 |
| Chen, DL; Chu, W; D'Avignon, A; Mach, RH; Reichert, DE; Rothfuss, J; Wang, Q; Welch, MJ; Zhou, D | 1 |
| Aboagye, EO; Glaser, M; Goggi, J; Luthra, SK; Morrison, M; Robins, E; Smith, G | 1 |
| Fernandes, PD; Figueiredo, GS; Pinto, AC; Silva, BV; Violante, FA; Zardo, RS | 1 |
| Hamaue, N; Minami, M; Nagashima, K; Ogata, A; Tashiro, K; Terado, M | 1 |
| Endo, T; Hamaue, N; Hirafuji, M; Hiroshige, T; Machida, M; Minami, M; Ogata, A; Parvez, SH; Saito, H; Tashiro, K; Terado, M | 1 |
| Hamaue, N; Hirafuji, M; Hiroshige, T; Minami, M; Ogata, A; Parvez, SH; Saito, H; Tashiro, K | 1 |
| Endo, T; Hamaue, N; Hirafuji, M; Ide, H; Minami, M; Ogata, A; Tashiro, K; Terado, M; Yamazaki, N; Yoshioka, M | 1 |
15 other study(ies) available for isatin and Disease Models, Animal
| Article | Year |
|---|---|
Discovery of isatin-β-methyldithiocarbazate derivatives as New Delhi metallo- β-lactamase-1 (NDM-1) inhibitors against NDM-1 producing clinical isolates.
Topics: Amino Acids; Animals; Disease Models, Animal; Isatin; Meropenem; Mice; Molecular Docking Simulation | 2023 |
Pre-clinical evidence of safety and protective effect of isatin and oxime derivatives against malathion-induced toxicity.
Topics: Animals; Artemia; Cholinesterase Inhibitors; Cholinesterase Reactivators; Disease Models, Animal; Drug Discovery; Female; Insecticides; Isatin; Lethal Dose 50; Malathion; Male; Oximes; Rats; Rats, Wistar | 2020 |
[The effect of neurotoxin MPTP administration to mice on the proteomic profile of brain isatin-binding proteins].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Carrier Proteins; Disease Models, Animal; Isatin; Locomotion; Mice; Mice, Inbred C57BL; Parkinsonian Disorders; Proteome | 2017 |
N-Pyrazoloyl and N-thiopheneacetyl hydrazone of isatin exhibited potent anti-inflammatory and anti-nociceptive properties through suppression of NF-κB, MAPK and oxidative stress signaling in animal models of inflammation.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Cytokines; Disease Models, Animal; Edema; Hot Temperature; Hydrazones; Hyperalgesia; Isatin; Male; Mice, Inbred BALB C; Mitogen-Activated Protein Kinases; NF-kappa B; Oxidative Stress; Signal Transduction; Stomach | 2019 |
Inhibition of tumor necrosis factor-alpha and cyclooxigenase-2 by Isatin: a molecular mechanism of protection against TNBS-induced colitis in rats.
Topics: Animals; Blotting, Western; Colitis; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Enzyme Activation; Glutathione; Isatin; Rats; Trinitrobenzenesulfonic Acid; Tumor Necrosis Factor-alpha | 2014 |
Anti-inflammatory properties of convolutamydine A and two structural analogues.
Topics: Animals; Anti-Inflammatory Agents; Behavior, Animal; Carrageenan; Cell Line; Cyclooxygenase 2; Cytokines; Dinoprostone; Disease Models, Animal; Dose-Response Relationship, Drug; Formaldehyde; Inflammation; Interleukin-6; Isatin; Macrophages; Male; Mice; Mice, Inbred BALB C; Nitric Oxide; Nitric Oxide Synthase Type II; Tumor Necrosis Factor-alpha | 2014 |
Synthesis, Biological Activity, and Docking Study of Novel Isatin Coupled Thiazolidin-4-one Derivatives as Anticonvulsants.
Topics: Animals; Anticonvulsants; Behavior, Animal; Binding Sites; Computer-Aided Design; Disease Models, Animal; Drug Design; Electroshock; Isatin; Ligands; Liver; Male; Mice; Molecular Docking Simulation; Molecular Structure; Pentylenetetrazole; Protein Binding; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Seizures; Structure-Activity Relationship; Thiazolidines | 2015 |
In Vivo Evaluation of Radiofluorinated Caspase-3/7 Inhibitors as Radiotracers for Apoptosis Imaging and Comparison with [18F]ML-10 in a Stroke Model in the Rat.
Topics: Animals; Apoptosis; Caspase 3; Caspase 7; Caspase Inhibitors; Disease Models, Animal; Isatin; Male; Methylmalonic Acid; Molecular Imaging; Radionuclide Imaging; Radiopharmaceuticals; Rats, Sprague-Dawley; Stroke; Tissue Distribution | 2016 |
[18F]- and [11C]-labeled N-benzyl-isatin sulfonamide analogues as PET tracers for apoptosis: synthesis, radiolabeling mechanism, and in vivo imaging study of apoptosis in Fas-treated mice using [11C]WC-98.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Apoptosis; Carbon Radioisotopes; Computer Simulation; Crystallography, X-Ray; Disease Models, Animal; fas Receptor; Female; Fluorine Radioisotopes; Indoles; Isatin; Isotope Labeling; Liver; Magnetic Resonance Spectroscopy; Mice; Mice, Inbred BALB C; Models, Chemical; Models, Molecular; Molecular Structure; Positron-Emission Tomography; Radiopharmaceuticals; Stereoisomerism; Sulfonamides | 2009 |
Improved radiosynthesis of the apoptosis marker 18F-ICMT11 including biological evaluation.
Topics: Animals; Apoptosis; Azides; Biomarkers; Diagnostic Imaging; Disease Models, Animal; Fluorodeoxyglucose F18; Indoles; Isatin; Lymphoma; Mice; Molecular Structure; Positron-Emission Tomography; Radiopharmaceuticals | 2011 |
Convolutamydine A and synthetic analogues have antinociceptive properties in mice.
Topics: Analgesics; Animals; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Isatin; Male; Mice; Motor Activity; Pain; Pain Measurement | 2013 |
Isatin, an endogenous MAO inhibitor, improves bradykinesia and dopamine levels in a rat model of Parkinson's disease induced by Japanese encephalitis virus.
Topics: Animals; Brain; Disease Models, Animal; Encephalitis Virus, Japanese; Hypokinesia; Isatin; Monoamine Oxidase Inhibitors; Parkinsonian Disorders; Rats; Rats, Inbred F344; Tyrosine 3-Monooxygenase | 2003 |
Comparative study of the effects of isatin, an endogenous MAO-inhibitor, and selegiline on bradykinesia and dopamine levels in a rat model of Parkinson's disease induced by the Japanese encephalitis virus.
Topics: Animals; Disease Models, Animal; Dopamine; Encephalitis Virus, Japanese; Hypokinesia; Isatin; Mice; Monoamine Oxidase Inhibitors; Parkinson Disease; Rats; Selegiline | 2004 |
Isatin, an endogenous MAO inhibitor, and a rat model of Parkinson's disease induced by the Japanese encephalitis virus.
Topics: Animals; Animals, Newborn; Disease Models, Animal; Encephalitis Virus, Japanese; Isatin; Monoamine Oxidase Inhibitors; Motor Activity; Parkinson Disease; Rats; Tyrosine 3-Monooxygenase | 2006 |
[Effects of isatin, an endogenous MAO inhibitor, on dopamine (DA) and acetylcholine (ACh) concentrations in rats].
Topics: Acetylcholine; Animals; Brain Chemistry; Disease Models, Animal; Dopamine; Humans; Isatin; Monoamine Oxidase Inhibitors; Parkinson Disease; Rats; Rats, Inbred F344; Rats, Inbred SHR; Rats, Inbred WKY | 1999 |